BofA Boosts AbbVie and J&J Price Targets on Growth and Pipeline Strength

Bank of America raised price targets for two pharmaceutical giants approaching patent cliffs, signaling some upside despite looming loss-of-exclusivity risks. The bank's conviction differs materially between the companies, with their valuation gap presented as a key factor in determining the more attractive long-term portfolio holding.